[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alx Oncology Holdings Inc (ALXO)

Alx Oncology Holdings Inc (ALXO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 269,126
  • Shares Outstanding, K 134,563
  • Annual Sales, $ 0 K
  • Annual Income, $ -101,700 K
  • EBIT $ -91 M
  • EBITDA $ -91 M
  • 60-Month Beta 0.42
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.75

Options Overview Details

View History
  • Implied Volatility 124.60% (-26.35%)
  • Historical Volatility 94.96%
  • IV Percentile 3%
  • IV Rank 6.80%
  • IV High 708.68% on 09/09/25
  • IV Low 82.00% on 05/20/26
  • Expected Move (DTE 1) 0.00 (0.00%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 9
  • Volume Avg (30-Day) 45
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 2,439
  • Open Int (30-Day) 2,395
  • Expected Range 2.03 to 2.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.15
  • Number of Estimates 2
  • High Estimate $-0.14
  • Low Estimate $-0.16
  • Prior Year $-0.49
  • Growth Rate Est. (year over year) +69.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.37 +48.18%
on 06/17/26
2.41 -15.77%
on 07/09/26
+0.45 (+28.48%)
since 06/15/26
3-Month
1.37 +48.18%
on 06/17/26
2.41 -15.77%
on 07/09/26
+0.35 (+20.83%)
since 04/15/26
52-Week
0.44 +357.21%
on 07/22/25
2.66 -23.68%
on 02/19/26
+1.56 (+335.16%)
since 07/15/25

Most Recent Stories

More News
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies...

ALXO : 2.03 (+1.50%)
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel

Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Succeeds Co-Founder Corey Goodman, Ph.D., After More Than a Decade of Foundational Leadership SOUTH...

ALXO : 2.03 (+1.50%)
ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs

ALX Oncology (NASDAQ:ALXO) executives said the company is focused on advancing two clinical-stage oncology programs, with upcoming data readouts expected to shape potential later-stage development plans...

ALXO : 2.03 (+1.50%)
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies...

ALXO : 2.03 (+1.50%)
ALX Oncology Q1 Earnings Call Highlights

ALX Oncology (NASDAQ:ALXO) executives used the company’s first-quarter 2026 earnings call to highlight new clinical data for its lead CD47 blocker, evorpacept, and to provide updates on its EGFR-targeted...

ALXO : 2.03 (+1.50%)
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses...

ALXO : 2.03 (+1.50%)
ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from...

ALXO : 2.03 (+1.50%)
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026

- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology";...

ALXO : 2.03 (+1.50%)
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies...

ALXO : 2.03 (+1.50%)
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April ...

ALXO : 2.03 (+1.50%)

Business Summary

ALX Oncology Holdings Inc.is a clinical-stage immuno-oncology company. It focuses on developing therapies for patients fighting cancer. The company's product candidate consist ALX148, which is in clinical stage. ALX Oncology Holdings Inc.is based in Burlingame, California.

See More

Key Turning Points

3rd Resistance Point 2.22
2nd Resistance Point 2.14
1st Resistance Point 2.08
Last Price 2.03
1st Support Level 1.95
2nd Support Level 1.87
3rd Support Level 1.81

See More

52-Week High 2.66
Last Price 2.03
Fibonacci 61.8% 1.81
Fibonacci 50% 1.55
Fibonacci 38.2% 1.29
52-Week Low 0.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.